Solaris Resources (CVE:SLS) Shares Down 2.7% – Here’s What Happened

Solaris Resources Inc. (CVE:SLS)’s stock price dropped 2.7% on Wednesday . The company traded as low as C$5.95 and last traded at C$6.15. Approximately 53,313 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 132,199 shares. The stock had previously closed at C$6.32.

Solaris Resources Stock Performance

The business’s fifty day moving average price is C$6.15 and its 200-day moving average price is C$6.15.

About Solaris Resources

SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.